×
About 534 results

ALLMedicine™ Generalized Lipodystrophy Center

Research & Reviews  255 results

Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matche...
https://doi.org/10.1210/clinem/dgab216
The Journal of Clinical Endocrinology and Metabolism; Cook K, Ali O et. al.

Apr 6th, 2021 - Data quantifying the impact of metreleptin therapy on survival in nonHIVrelated generalized lipodystrophy (GL) and partial lipodystrophy (PL) are unavailable. This study aimed to estimate the treatment effect of metreleptin on survival in patients...

Altered acylated ghrelin response to food intake in congenital generalized lipodystrophy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790291
PloS One; Araújo COD, Montenegro RM et. al.

Jan 7th, 2021 - Patients with congenital generalized lipodystrophy (CGL) have very low levels of leptin and are described as having a voracious appetite. However, a direct comparison between CGL and eutrophic individuals is lacking, regarding both appetite parame...

Evolving clinical manifestations of mandibular hypoplasia, deafness, progeroid features...
https://doi.org/10.1002/ajmg.a.62035
American Journal of Medical Genetics. Part A; Yu PT, Luk HM et. al.

Dec 28th, 2020 - Mandibular hypoplasia, deafness, progeroid feature, and lipodystrophy syndrome (MDPL, MIM# 615381) is an extremely rare and recently recognized early adult onset of progeroid syndrome, with features of generalized lipodystrophy, dysmorphic feature...

Studies of 96 children with Juvenile Dermatomyositis: P155/140, is associated with loss...
https://doi.org/10.1002/acr.24535
Arthritis Care & Research; Khojah A, Liu V et. al.

Dec 8th, 2020 - Myositis-specific antibodies (MSA) facilitate grouping children with Juvenile Dermatomyositis (JDM) into distinct phenotypes. Aim one of this study investigates the link between anti-P155/140 and lipodystrophy as determined by DXA assessment of fa...

Eating behaviour in contrasting adiposity phenotypes: Monogenic obesity and congenital ...
https://doi.org/10.1111/obr.13114
Obesity Reviews : an Official Journal of the Internationa... Santos JL, Cortés VA

Oct 8th, 2020 - Most known types of nonsyndromic monogenic obesity are caused by rare mutations in genes of the leptin-melanocortin pathway controlling appetite and adiposity. In contrast, congenital generalized lipodystrophy represents the most extreme form of l...

see more →

Guidelines  1 results

MYALEPT® (metreleptin)
http://www.myaleptpro.com/

Learn more about MYALEPT (metreleptin) for injection, indicated as an adjunct to diet to treat complications of leptin deficiency in patients with generalized lipodystrophy

see more →

Drugs  4 results see all →

Clinicaltrials.gov  269 results

Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matche...
https://doi.org/10.1210/clinem/dgab216
The Journal of Clinical Endocrinology and Metabolism; Cook K, Ali O et. al.

Apr 6th, 2021 - Data quantifying the impact of metreleptin therapy on survival in nonHIVrelated generalized lipodystrophy (GL) and partial lipodystrophy (PL) are unavailable. This study aimed to estimate the treatment effect of metreleptin on survival in patients...

Altered acylated ghrelin response to food intake in congenital generalized lipodystrophy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790291
PloS One; Araújo COD, Montenegro RM et. al.

Jan 7th, 2021 - Patients with congenital generalized lipodystrophy (CGL) have very low levels of leptin and are described as having a voracious appetite. However, a direct comparison between CGL and eutrophic individuals is lacking, regarding both appetite parame...

Evolving clinical manifestations of mandibular hypoplasia, deafness, progeroid features...
https://doi.org/10.1002/ajmg.a.62035
American Journal of Medical Genetics. Part A; Yu PT, Luk HM et. al.

Dec 28th, 2020 - Mandibular hypoplasia, deafness, progeroid feature, and lipodystrophy syndrome (MDPL, MIM# 615381) is an extremely rare and recently recognized early adult onset of progeroid syndrome, with features of generalized lipodystrophy, dysmorphic feature...

Studies of 96 children with Juvenile Dermatomyositis: P155/140, is associated with loss...
https://doi.org/10.1002/acr.24535
Arthritis Care & Research; Khojah A, Liu V et. al.

Dec 8th, 2020 - Myositis-specific antibodies (MSA) facilitate grouping children with Juvenile Dermatomyositis (JDM) into distinct phenotypes. Aim one of this study investigates the link between anti-P155/140 and lipodystrophy as determined by DXA assessment of fa...

Eating behaviour in contrasting adiposity phenotypes: Monogenic obesity and congenital ...
https://doi.org/10.1111/obr.13114
Obesity Reviews : an Official Journal of the Internationa... Santos JL, Cortés VA

Oct 8th, 2020 - Most known types of nonsyndromic monogenic obesity are caused by rare mutations in genes of the leptin-melanocortin pathway controlling appetite and adiposity. In contrast, congenital generalized lipodystrophy represents the most extreme form of l...

see more →

News  5 results

Myalept (Metreleptin) Approved for Generalized Lipodystrophy
https://www.medscape.com/viewarticle/821056

Feb 24th, 2014 - The US Food and Drug Administration (FDA) has approved Amylin Pharmaceuticals' Myalept (metreleptin for injection) as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized...

Myalept (Metreleptin) Approved for Generalized Lipodystrophy
https://www.staging.medscape.com/viewarticle/821056

Feb 24th, 2014 - The US Food and Drug Administration (FDA) has approved Amylin Pharmaceuticals' Myalept (metreleptin for injection) as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized...

Leptin Analog Endorsed for Generalized Lipodystrophy
https://www.medscape.com/viewarticle/817709

Dec 11th, 2013 - A Food and Drug Administration (FDA) advisory panel has voted 11 to 1 in favor of the use of metreleptin (Myalept, Bristol-Myers Squibb/AstraZeneca) for the treatment of pediatric and adult patients with generalized lipodystrophy. However, the FDA...

FDA advisory panel partially backs drug for rare fat disorder
https://www.reuters.com/article/us-fda-bristolmyers/fda-advisory-panel-partially-backs-drug-for-rare-fat-disorder-idUSBRE9BA1A020131211

Dec 11th, 2013 - (Reuters) - An advisory panel of medical experts convened by the U.S. Food and Drug Administration on Wednesday said that Bristol-Myers Squibb Co had provided adequate evidence of the benefits of an experimental drug to treat rare and potentially ...

MYALEPT® (metreleptin)
http://www.myaleptpro.com/

Learn more about MYALEPT (metreleptin) for injection, indicated as an adjunct to diet to treat complications of leptin deficiency in patients with generalized lipodystrophy

see more →